... HAMBURG Germany April 9 /- Indivumed GmbH the lead...Annette Kassen has spent the last 14 years of her career in basic and...After receiving her Ph.D. from Ruhr-Universitat Bochum in 1994 Annett... Annette Kassen brings with her very valuable knowledge concerning the...

HAMBURG, Germany, April 9 /PRNewswire/ -- Indivumed GmbH, the leading
provider of products and services enabling the individualized diagnosis and
therapy of cancer, announces the appointment of Annette Kassen, Ph.D., to
the newly created position of Vice President Clinical Research.

Annette Kassen has spent the last 14 years of her career in basic and
clinical research in the field of oncology. At Indivumed she will be
responsible for the further development and expansion of the company's
clinical research activities and services. Dr Kassen joins from medac GmbH,
a Hamburg based pharmaceutical company, where she worked as a project
leader conducting phase II/III clinical trials in Europe.

After receiving her Ph.D. from Ruhr-Universitat Bochum in 1994, Annette
Kassen was a post-doctoral fellow at Northwestern-University Medical
School, Chicago, focussing on the androgen regulation of human prostate
cancer cells. She continued her career as Head of Research Laboratories at
the University Hospital Department of Urology, Ruhr-Universitat Bochum. She
joined medac in 1999 and received her "Masters of Public Health" from
Hamburg University of Applied Sciences in 2004.

"Annette Kassen brings with her very valuable knowledge concerning the
continuously growing regulatory requirements in clinical research," says
Prof. Hartmut Juhl, Chief Executive Officer and Founder of Indivumed.
"Moreover, she is a skilful complement to our team and I am confident that
Indivumed will benefit from her experience in order to implement and
further develop highest clinical research quality standards at Indivumed."

Dr. Kassen said: "There is a great need for effective, sophisticated,
and individualized therapies in the treatment of oncologic diseases.
Indivumed has the potential to face this challenge successfully and I am
very happy to contribute to both the development of new therapeutic
strategies as well as the company's success."

About Indivumed

Indivumed is a privately held biotech company focused on the
generation, characterization and analysis of highly standardized biological
samples from human cancer. Founded in 2002 and headquartered in Hamburg,
Germany, with a subsidiary in Kensington, Maryland, USA, Indivumed has
cooperation agreements with all major oncological hospitals in the Hamburg
metropolitan area as well as with Georgetown University Hospital,
Washington, D.C. Indivumed's current tumor biobank of over 8,000
patient-cases, collected with a mean cold ischemia time of less than eight
minutes, serves as a resource for Indivumed's internal cancer research in
biomarkers and primary cell drug screening as well as for the use of
pharmaceutical and biopharma partners through tumor biobank access and a
variety of services, such as e.g. IHC and drug profiling.

(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments from ... lab to fully automated pilot plants and equipment for industrial manufacturing. All ...

(Date:8/16/2017)... ... August 16, 2017 , ... ... and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection took ... This inspection was conducted as part of a routine Bioresearch Monitoring Program (BIMO) ...

(Date:8/15/2017)... ... 15, 2017 , ... Kapstone Medical is proud to announce that ... technology companies and inventors develop and safeguard their latest innovations. The company has ... a portfolio of clients in the United States and around the world. , ...

(Date:8/15/2017)... Wisconsin (PRWEB) , ... August 15, 2017 , ... ... a new family of 6” modular downlights designed to stay tightly sealed and ... including areas where damp and wet location listings just aren't enough, such as: ...

(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...

(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...